Compare HLX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | CDNA |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | 2212 | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2007 |
| Metric | HLX | CDNA |
|---|---|---|
| Price | $9.91 | $37.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $876,561,000.00 | $48,324,000.00 |
| Revenue This Year | $2.05 | $16.01 |
| Revenue Next Year | $5.46 | $11.31 |
| P/E Ratio | ★ N/A | $752.20 |
| Revenue Growth | 3.60 | ★ 18.93 |
| 52 Week Low | $5.58 | $11.26 |
| 52 Week High | $10.75 | $40.47 |
| Indicator | HLX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 72.16 |
| Support Level | $9.21 | $15.89 |
| Resistance Level | $9.89 | $40.47 |
| Average True Range (ATR) | 0.27 | 1.70 |
| MACD | 0.09 | 0.51 |
| Stochastic Oscillator | 91.61 | 77.26 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.